Home LiteratureArticle Details
PMID: 32214151 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.

Scientific reports ·Vol. 10 ·No. 1 ·2020-00-25 ·Pages 5379

Fiedorowicz M, Khan MI, Strzemecki D, Orzeł J, Wełniak-Kamińska M, Sobiborowicz A, Wieteska M, Rogulski Z, Cheda L, Wargocka-Matuszewska W, Kilian K, Szczylik C, Czarnecka AM

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer. Prognosis for ccRCC is generally poor since it is largely resistant to chemo- and radiotherapy. Many studies suggested that cancer stem cells/tumor initiating cells (CSCs/TICs) are responsible for development of tumor, disease progression, aggressiveness, metastasis and drug resistance. However, tumorigenic potential of CSCs/TICs isolated from established RCC cell lines - basic ccRCC research model - has never been investigated in vivo. CD105+, CD105-, CD44+ and CD44- as well as CD44-/CD105- CD44+/CD105+ and CD44-/CD105+ cells were isolated from Caki-1 RCC cell line, confirming coexistence of multiple subpopulations of stem-related phenotype in stable cell line. Sorted cells were injected subcutaneously into NOD SCID mice and tumor growth was monitored with MRI and PET/CT. Tumor growth was observed after implantation of CD105+, CD44+, CD44-, CD44-/CD105+ and CD44-/CD105- but not CD105- or CD44+/CD105+. Implantation of CD44-/CD105- cells induced tumors that were characterized by longer T1 and distinct metabolic pattern than other tumors. All the tumors were characterized by low uptake of [18F]FDG. CD105+ and CD44- tumors expresses Nanog and Oct-4, while CD44- tumors additionally expressed endothelial cell marker - CD31.

MeSH Terms
Animals Biomarkers, Tumor/immunology,metabolism Carcinoma, Renal Cell/immunology,pathology Cell Line, Tumor Cell Separation Endoglin/immunology,metabolism Humans Hyaluronan Receptors/immunology,metabolism Kidney Neoplasms/immunology,pathology Male Mice Mice, Inbred NOD Mice, SCID Neoplastic Stem Cells/immunology,metabolism Positron Emission Tomography Computed Tomography Prognosis
Chemicals
Biomarkers, Tumor CD44 protein, human ENG protein, human Endoglin Hyaluronan Receptors
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Fiedorowicz M ORCID
Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. mfiedorowicz@imdik.pan.pl.
Khan M I
Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Warsaw, Poland. | Department of Otolaryngology - Head & Neck Surgery, Western University, London, ON, N6A 3K7, Canada.
Strzemecki D
Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Orzeł J
Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. | Faculty of Electronics and Information Technology, Warsaw University of Technology, Warsaw, Poland.
Wełniak-Kamińska M
Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Sobiborowicz A
Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland. | Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Wieteska M
Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. | Faculty of Electronics and Information Technology, Warsaw University of Technology, Warsaw, Poland.
Rogulski Z
Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland.
Cheda L
Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland.
Wargocka-Matuszewska W
Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland.
Kilian K ORCID
Heavy Ion Laboratory, Faculty of Physics, University of Warsaw, Warsaw, Poland.
Szczylik C
Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Warsaw, Poland. | Department of Oncology, European Health Centre, Otwock, Poland. | Medical Center for Postgraduate Education, Warsaw, Poland.
Czarnecka A M ORCID
Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. | Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Warsaw, Poland. | Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
References (81)
81 references, click to expand
  1. Renal cell carcinoma.
    Hsieh, J. J. et al. Renal cell carcinoma. Nature Reviews Disease Primers 3, 17009, https://doi.org/10.1038/nrdp.2017.9 (2017). PMID: 28276433 DOI
  2. Czarnecka, A. M. & Szczylik, C. Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets. Current signal transduction therapy 8, 203–209 (2013). DOI
  3. Meyerrose, T. E., Herrbrich, P., Hess, D. A. & Nolta, J. A. Immune-deficient mouse models for analysis of human stem cells. BioTechniques 35, 1262–1272 (2003). DOI
  4. Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma.
    Gedye, C. et al. Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma. Scientific reports 6, 25220, https://doi.org/10.1038/srep25220 (2016). PMID: 27121191 DOI
  5. Cancer stem cells and their potential implications for the treatment of solid tumors.
    Grotenhuis, B. A., Wijnhoven, B. P. & van Lanschot, J. J. Cancer stem cells and their potential implications for the treatment of solid tumors. Journal of surgical oncology 106, 209–215, https://doi.org/10.1002/jso.23069 (2012). PMID: 22371125 DOI
  6. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.
    Buczek, M., Escudier, B., Bartnik, E., Szczylik, C. & Czarnecka, A. M. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochimica et biophysica acta 1845, 31–41, https://doi.org/10.1016/j.bbcan.2013.10.001 (2014). PMID: 24135488 DOI
  7. Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC).
    Bielecka, Z. F., Czarnecka, A. M., Solarek, W., Kornakiewicz, A. & Szczylik, C. Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). Current signal transduction therapy 8, 218–228, https://doi.org/10.2174/1574362409666140206223014 (2014). PMID: 25152704 DOI
  8. Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells.
    Bielecka, Z. F. et al. Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell Biosci 7, 71, https://doi.org/10.1186/s13578-017-0197-8 (2017). PMID: 29270287 DOI
  9. Choosing the right cell line for renal cell cancer research.
    Brodaczewska, K. K., Szczylik, C., Fiedorowicz, M., Porta, C. & Czarnecka, A. M. Choosing the right cell line for renal cell cancer research. Mol Cancer 15, 83, https://doi.org/10.1186/s12943-016-0565-8 (2016). PMID: 27993170 DOI
  10. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells.
    Debeb, B. G. et al. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer 9, 180, https://doi.org/10.1186/1476-4598-9-180 (2010). PMID: 20615238 DOI
  11. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line.
    Ueda, K. et al. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PloS one 8, e75463, https://doi.org/10.1371/journal.pone.0075463 (2013). PMID: 24116047 DOI
  12. Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells.
    Khan, M. I. et al. Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. PLoS One 11, e0165718, https://doi.org/10.1371/journal.pone.0165718 (2016). PMID: 27812180 DOI
  13. Bussolati, B., Bruno, S., Grange, C., Ferrando, U. & Camussi, G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 22, 3696–3705, https://doi.org/10.1096/fj.08-102590 (2008). DOI
  14. Czarnecka, A., Matak, D., Solarek, W., Khan, M. & Szczylik, C. Hypoxia response regulates clear cell renal cell carcinoma tumor initiating cells. BJU international 112, 1–17 (2013).
  15. CD133+ renal progenitor cells contribute to tumor angiogenesis.
    Bruno, S. et al. CD133+ renal progenitor cells contribute to tumor angiogenesis. The American journal of pathology 169, 2223–2235, https://doi.org/10.2353/ajpath.2006.060498 (2006). PMID: 17148683 DOI
  16. Czarnecka, A. M. & Solarek, W. The activity of tyrosine kinase inhibitors on clear cell renal cell carcinoma tumor initiating cells in hypoxic microenvironment. BJU Intnernational 110, 1–20, https://doi.org/10.1111/j.1464-410X.2012.11574.x (2012). DOI
  17. Gassenmaier, M. et al. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem cells (Dayton, Ohio) 31, 1467–1476, https://doi.org/10.1002/stem.1407 (2013). DOI
  18. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells.
    Khan, M. I. et al. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res Ther 6, 178, https://doi.org/10.1186/s13287-015-0177-z (2015). PMID: 26377541 DOI
  19. Matak, D., Szymanski, L., Czarnecka, A. M., Bartnik, E. & Szczylik, C. Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics. Current signal transduction therapy 8, 229–239 (2013). DOI
  20. Functional significance of CD105-positive cells in papillary renal cell carcinoma.
    Matak, D. et al. Functional significance of CD105−positive cells in papillary renal cell carcinoma. BMC Cancer 17, 21, https://doi.org/10.1186/s12885-016-2985-7 (2017). PMID: 28056882 DOI
  21. Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model.
    Krawczyk, K. M. et al. Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model. Cytotechnology 70, 761–782, https://doi.org/10.1007/s10616-017-0181-5 (2018). PMID: 29455394 DOI
  22. Biomarker discovery for renal cancer stem cells.
    Corro, C. & Moch, H. Biomarker discovery for renal cancer stem cells. J Pathol Clin Res 4, 3–18, https://doi.org/10.1002/cjp2.91 (2018). PMID: 29416873 DOI
  23. Biological characteristics of Rh123high stem-like cells in a side population of 786-O renal carcinoma cells.
    Lu, J. et al. Biological characteristics of Rh123 stem-like cells in a side population of 786-O renal carcinoma cells. Oncology letters 5, 1903–1908, https://doi.org/10.3892/ol.2013.1270 (2013). PMID: 23833664 DOI
  24. Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P.
    Huang, B. et al. Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. PloS one 8, e68293, https://doi.org/10.1371/journal.pone.0068293 (2013). PMID: 23874578 DOI
  25. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.
    Nishizawa, S. et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer research 72, 2844–2854, https://doi.org/10.1158/0008-5472.CAN-11-3062 (2012). PMID: 22552285 DOI
  26. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers.
    Oates, J. E. et al. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev 18, 1515–1522, https://doi.org/10.1089/scd.2008.0302 (2009). PMID: 19260804 DOI
  27. SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics.
    Hughes, C. et al. SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics. The Analyst 135, 3133–3141, https://doi.org/10.1039/c0an00574f (2010). PMID: 20981365 DOI
  28. Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells.
    Hu, J. et al. Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells. Stem Cell Reports 9, 464–477, https://doi.org/10.1016/j.stemcr.2017.07.009 (2017). PMID: 28793246 DOI
  29. Expression and clinical value of CD105 in renal cell carcinoma based on data mining in The Cancer Genome Atlas.
    Shi, D. et al. Expression and clinical value of CD105 in renal cell carcinoma based on data mining in The Cancer Genome Atlas. Exp Ther Med 17, 4499–4505, https://doi.org/10.3892/etm.2019.7493 (2019). PMID: 31086581 DOI
  30. Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma.
    Yang, X. et al. Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma. Oncology letters 15, 4229–4234, https://doi.org/10.3892/ol.2018.7871 (2018). PMID: 29541188 DOI
  31. Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma.
    Hu, J. et al. Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma. Stem Cells Int 2019, 9060152, https://doi.org/10.1155/2019/9060152 (2019). PMID: 31015843 DOI
  32. Pearson, G. W. Control of Invasion by Epithelial-to-Mesenchymal Transition Programs during Metastasis. Journal of clinical medicine 8, https://doi.org/10.3390/jcm8050646 (2019). DOI
  33. Maliszewska-Olejniczak, K. et al. Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. Cytotechnology, https://doi.org/10.1007/s10616-018-0273-x (2018). DOI
  34. miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties.
    Lichner, Z. et al. miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties. Oncotarget 6, 5567–5581, https://doi.org/10.18632/oncotarget.1901 (2015). PMID: 25011053 DOI
  35. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.
    Saeednejad Zanjani, L. et al. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma. Cancer Biomark 21, 821–837, https://doi.org/10.3233/CBM-170755 (2018). PMID: 29286924 DOI
  36. Rouschop, K. M. et al. CD44 deficiency increases tubular damage but reduces renal fibrosis in obstructive nephropathy. Journal of the American Society of Nephrology: JASN 15, 674–686 (2004). DOI
  37. Expression of CD44 in kidney after acute ischemic injury in rats.
    Lewington, A. J., Padanilam, B. J. & Martin, D. R. & Hammerman, M. R. Expression of CD44 in kidney after acute ischemic injury in rats. Am J Physiol Regul Integr Comp Physiol 278, R247–254, https://doi.org/10.1152/ajpregu.2000.278.1.R247 (2000). PMID: 10644646 DOI
  38. CD44 immunoreactivity in the developing human kidney: a marker of renal progenitor stem cells?
    Fanni, D. et al. CD44 immunoreactivity in the developing human kidney: a marker of renal progenitor stem cells? Ren Fail 35, 967–970, https://doi.org/10.3109/0886022X.2013.808955 (2013). PMID: 23826724 DOI
  39. CD44 and hyaluronan help mesenchymal stem cells move to a neighborhood in need of regeneration.
    Poulsom, R. CD44 and hyaluronan help mesenchymal stem cells move to a neighborhood in need of regeneration. Kidney Int 72, 389–390, https://doi.org/10.1038/sj.ki.5002398 (2007). PMID: 17687379 DOI
  40. Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway.
    Zhang, H. J. et al. Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. Onco Targets Ther 9, 1801–1812, https://doi.org/10.2147/OTT.S96535 (2016). PMID: 27099513 DOI
  41. Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer.
    Krishnamachary, B. et al. Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer. PLoS One 7, e44078, https://doi.org/10.1371/journal.pone.0044078 (2012). PMID: 22937154 DOI
  42. HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma.
    Micucci, C., Matacchione, G., Valli, D., Orciari, S. & Catalano, A. HIF2alpha is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J Cancer 113, 1178–1185, https://doi.org/10.1038/bjc.2015.338 (2015). PMID: 26439684 DOI
  43. Gutteridge, R. J. Caveolin-1 is a modulator of clonogenicityin Renal Cell Carcinoma, Cardiff University, (2016).
  44. Integrins and laminins in human renal carcinoma cells and tumors grown in nude mice.
    Korhonen, M., Sariola, H., Gould, V. E., Kangas, L. & Virtanen, I. Integrins and laminins in human renal carcinoma cells and tumors grown in nude mice. Cancer research 54, 4532–4538 (1994). PMID: 8044804
  45. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
    Ziegler, J. et al. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro-oncology 19, 175–185, https://doi.org/10.1093/neuonc/now147 (2017). PMID: 27416955 DOI
  46. Kobayashi, H. et al. 3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent. Magnet Reson Med 46, 579–585, https://doi.org/10.1002/mrm.1230 (2001). DOI
  47. High-resolution three-dimensional MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature.
    Fink, C. et al. High-resolution three-dimensional MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature. Journal of magnetic resonance imaging: JMRI 18, 59–65, https://doi.org/10.1002/jmri.10318 (2003). PMID: 12815640 DOI
  48. Comparison of digital subtraction angiography, micro-computed tomography angiography and magnetic resonance angiography in the assessment of the cerebrovascular system in live mice.
    Figueiredo, G. et al. Comparison of digital subtraction angiography, micro-computed tomography angiography and magnetic resonance angiography in the assessment of the cerebrovascular system in live mice. Clinical neuroradiology 22, 21–28, https://doi.org/10.1007/s00062-011-0113-2 (2012). PMID: 22109696 DOI
  49. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
    Schor-Bardach, R. et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251, 731–742, https://doi.org/10.1148/radiol.2521081059 (2009). PMID: 19474376 DOI
  50. Detection of necrosis in human tumour xenografts by proton magnetic resonance imaging.
    Jakobsen, I., Kaalhus, O., Lyng, H. & Rofstad, E. K. Detection of necrosis in human tumour xenografts by proton magnetic resonance imaging. Br J Cancer 71, 456–461, https://doi.org/10.1038/bjc.1995.93 (1995). PMID: 7880724 DOI
  51. Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.
    Weidensteiner, C. et al. Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells–a preclinical MR study in mice. BMC cancer 14, 88, https://doi.org/10.1186/1471-2407-14-88 (2014). PMID: 24528602 DOI
  52. Rofstad, E. K. et al. Magnetic resonance imaging of human melanoma xenografts in vivo: proton spin-lattice and spin-spin relaxation times versus fractional tumour water content and fraction of necrotic tumour tissue. International journal of radiation biology 65, 387–401 (1994). DOI
  53. Sonkar, K. et al. Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed, e4112, https://doi.org/10.1002/nbm.4112 (2019).
  54. Fardanesh, R. et al. Proton MR spectroscopy in the breast: Technical innovations and clinical applications. Journal of magnetic resonance imaging: JMRI, https://doi.org/10.1002/jmri.26700 (2019). DOI
  55. In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma.
    Süllentrop, F., Hahn, J. & Moka, D. In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma. International journal of biomedical science: IJBS 8, 94–108 (2012). PMID: 23675262
  56. Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues.
    Righi, V. et al. Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues. Anticancer research 27, 3195–3204 (2007). PMID: 17970061
  57. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy.
    Sevcenco, S. et al. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. World J Urol 33, 17–23, https://doi.org/10.1007/s00345-014-1272-y (2015). PMID: 24609220 DOI
  58. Sulfolipids and glycolipid sulfotransferase activities in human renal cell carcinoma cells.
    Kobayashi, T. et al. Sulfolipids and glycolipid sulfotransferase activities in human renal cell carcinoma cells. Br J Cancer 67, 76–80, https://doi.org/10.1038/bjc.1993.12 (1993). PMID: 8094007 DOI
  59. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development.
    Khandani, A. H. & Rathmell, W. K. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Seminars in nuclear medicine 42, 221–230, https://doi.org/10.1053/j.semnuclmed.2012.02.002 (2012). PMID: 22681671 DOI
  60. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu, V., Jain, A. L., Eluvathingal, T. J. & Sidana, A. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma. Current urology reports 20, 56, https://doi.org/10.1007/s11934-019-0932-2 (2019). PMID: 31468240 DOI
  61. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.
    Tabei, T. et al. Early assessment with (18)F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC cancer 19, 298, https://doi.org/10.1186/s12885-019-5510-y (2019). PMID: 30940117 DOI
  62. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.
    Verhoeff, S. R. et al. Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European journal of nuclear medicine and molecular imaging 46, 1931–1939, https://doi.org/10.1007/s00259-019-04358-9 (2019). PMID: 31172212 DOI
  63. Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
    Wang, X. et al. Prognostic Values of TIGAR Expression and (18)F-FDG PET/CT in Clear Cell Renal Cell Carcinoma. Journal of Cancer 11, 1–8, https://doi.org/10.7150/jca.33442 (2020). PMID: 31892967 DOI
  64. Zhu, S. et al. Differential diagnostic ability of 18F-FDG PET/CT radiomics features between renal cell carcinoma and renal lymphoma. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So, https://doi.org/10.23736/s1824-4785.19.03137-6 (2019).
  65. PET imaging in renal cancer.
    Lindenberg, L., Mena, E., Choyke, P. L. & Bouchelouche, K. PET imaging in renal cancer. Current opinion in oncology 31, 216–221, https://doi.org/10.1097/cco.0000000000000518 (2019). PMID: 30747736 DOI
  66. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline.
    Donat, S. M. et al. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. The Journal of urology 190, 407–416, https://doi.org/10.1016/j.juro.2013.04.121 (2013). PMID: 23665399 DOI
  67. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27, v58–v68, https://doi.org/10.1093/annonc/mdw328 (2016). PMID: 27664262 DOI
  68. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
    Ljungberg, B. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European urology 75, 799–810, https://doi.org/10.1016/j.eururo.2019.02.011 (2019). PMID: 30803729 DOI
  69. Wang, H. Y. et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer imaging: the official publication of the International Cancer Imaging Society 12, 464–474, https://doi.org/10.1102/1470-7330.2012.0042 (2012). DOI
  70. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito, H. et al. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival. Cancer chemotherapy and pharmacology 79, 855–861, https://doi.org/10.1007/s00280-017-3275-z (2017). PMID: 28331985 DOI
  71. Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies.
    Nakhoda, Z., Torigian, D. A., Saboury, B., Hofheinz, F. & Alavi, A. Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies. Hellenic journal of nuclear medicine 16, 19–24, https://doi.org/10.1967/s002449910067 (2013). PMID: 23529389 DOI
  72. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozulker, T., Ozulker, F., Ozbek, E. & Ozpacaci, T. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nuclear medicine communications 32, 265–272, https://doi.org/10.1097/MNM.0b013e3283442e3b (2011). PMID: 21301376 DOI
  73. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
    Khandani, A. H., Cowey, C. L., Moore, D. T., Gohil, H. & Rathmell, W. K. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nuclear medicine communications 33, 967–973, https://doi.org/10.1097/MNM.0b013e3283561837 (2012). PMID: 22714005 DOI
  74. Majhail, N. S. et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 21, 3995–4000, https://doi.org/10.1200/jco.2003.04.073 (2003). DOI
  75. Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade.
    Ishibashi, K. et al. Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget 8, 55230–55245, https://doi.org/10.18632/oncotarget.19420 (2017). PMID: 28903416 DOI
  76. Brouwers, A. et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer biotherapy & radiopharmaceuticals 19, 155–163, https://doi.org/10.1089/108497804323071922 (2004). DOI
  77. Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma.
    Khan, M. I. et al. Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC cancer 18, 583, https://doi.org/10.1186/s12885-018-4496-1 (2018). PMID: 29792186 DOI
  78. Establishment of human tumor xenografts in immunodeficient mice.
    Morton, C. L. & Houghton, P. J. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2, 247–250, https://doi.org/10.1038/nprot.2007.25 (2007). PMID: 17406581 DOI
  79. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
    Wang, L., Park, P., La Marca, F., Than, K. D. & Lin, C. Y. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. Journal of cancer research and clinical oncology 141, 1013–1024, https://doi.org/10.1007/s00432-014-1883-0 (2015). PMID: 25431339 DOI
  80. Bernardo, C., Costa, C., Sousa, N., Amado, F. & Santos, L. Patient-derived bladder cancer xenografts: a systematic review. Translational research: the journal of laboratory and clinical medicine 166, 324–331, https://doi.org/10.1016/j.trsl.2015.02.001 (2015). DOI
  81. Provencher, S. W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30, 672–679 (1993). DOI
Article Info
Journal
Scientific reports
Abbr.
Sci Rep
ISSN
2045-2322
DOI
10.1038/s41598-020-62205-6
Email
mfiedorowicz@imdik.pan.pl
Published
2020-00-25
Epub
2020-00-25
Pages
5379
Language
English
Region
England
NLM ID
101563288
PMCID
PMC7096525
Subset
IM
External Links
PubMed source DOI: 10.1038/s41598-020-62205-6 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2